Drug Profile
ODM 104
Alternative Names: ODM-104Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Orion
- Class Antiparkinsonians
- Mechanism of Action Catechol O-methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Parkinson's-disease in Finland (PO, Capsule)
- 04 Mar 2021 No development reported - Phase-II for Parkinson's disease (Combination therapy) in Latvia, Finland, Germany, Hungary (PO)
- 04 Mar 2021 Orion Corporation initiates the phase I BRIAN pharmacokinetic trial in Finland (NCT04571996)